Scientific Advisory Board
The Scientific advisory board consists of our nation’s leading scientist and psychiatrists. Their role is to review scientific research proposals and advice the executive board on which to award research dollars. There are many unanswered questions about bipolar disorder-what causes it? What are the genetics of it? How should we treat it? At this point, there is still so much yet to be discovered. IBPF is determined to be part of the answer-by providing funding for research.
Husseini K. Manji, M.D.
Husseini K. Manji, M.D., is global therapeutic area head, neuroscience research and development, a position he assumed in March 2009. He joined Johnson & Johnson in October 2008 to lead research and development in the central nervous system therapeutic area.
Manji was previously chief, Laboratory of Molecular Pathophysiology & Experimental Therapeutics, NIMH, and director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world. He is also a visiting professor in the Department of Psychiatry at Duke University. Manji received his B.S. (Biochemistry) and M.D. from the University of British Columbia. Following residency training, he completed fellowship training at the NIMH and obtained extensive additional training in cellular and molecular biology at the NIDDK, National Institute of Diabetes, Digestibe and Kidney Diseases. The major focus of his research has been the investigation of disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. His work has helped to conceptualize these illnesses as genetically-influenced disorders of synaptic and neural plasticity, and has led to the investigation of novel therapeutics for refractory patients. He has also been actively involved in the development of biomarkers to help refine these multifactoral diseases into mechanism-based subcategories to develop targeted therapeutics.
Manji has received numerous research awards, including the NIMH Director's Career Award for Significant Scientific Achievement, the A. E. Bennett Award for Neuropsychiatric Research, the Ziskind-Somerfeld Award for Neuropsychiatric Research, the NARSAD Mood Disorders Prize, the Mogens Schou Distinguished Research Award, the American College of Neuropsychopharmacology (ACNP)’s Joel Elkes award for distinguished research.
John C. Reed, MD, Ph.D.
John C. Reed, MD, Ph.D., is President & Chief Executive Officer of Burnham Institute for Medical Research, where he has worked as scientist and leader for over 15 years. Dr. Reed is also Professor and Donald Bren Presidential Chair at Burnham, with adjunct Professor appointments at several universities. Dr. Reed’s scientific accomplishments include authorship of over 725 research publications and more than 50 book chapters. He was recognized as the world’s most highly cited scientist for his research publications during the decade 1995-2005 in the broad field of “cell biology” and also in the field of “general biomedicine” by the Institute for Scientific Information. Dr. Reed is the recipient of numerous awards and honors, and has been awarded over 70 research grants for his work. He is a named inventor for over 80 patents and the founder or co-founder of five biotechnology companies. Dr. Reed has served as an advisor to numerous biotechnology and pharmaceutical companies, and has also served on the Boards of Directors of several public and private biotechnology companies and life-sciences organizations.
Martin Alda, M.D., FRCPC
Dr. Martin Alda, Professor of Psychiatry, expert in mood disorders and in psychiatric genetics, is exploring the genetic and biological basis of mood disorders and the nature of response to long-term treatment.
Dr. Alda graduated from Charles University in Prague, Czechoslovakia. Prior to joining Dalhousie Medical School in 1998, Dr. Alda taught and practiced psychiatry in Czechoslovakia, at the University of Ottawa, and at McGill University. Currently he holds additional appointments at McGill University, The University of Pittsburgh, and at Charles University in Prague. Clinically Dr. Alda works in the Mood Disorders Program at the QEII Health Sciences Centre in Halifax.
The focus of Dr. Alda's group is on major psychiatric disorders and their genetics. Bipolar disorder, schizophrenia, and depression are all highly heritable, affect young people, lead to high morbidity and mortality, and can be more or less successfully treated. Three lines of enquiry – mapping genes for these conditions, linking the genetic predisposition with response to treatment, and examining how the genetic risk translates into behavioural and clinical features of the illness are at the core of the research program. To this end they use clinical, molecular-genetic, biochemical, brain-imaging, and neuropsychological methods in studies of patients and their family members.
Dr. Alda's research has been funded by the CIHR since 1997 and also supported by the Nova Scotia Health Research Foundation, Genome Quebec, Stanley Foundation, National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD), the Ontario Mental Health Foundation, and Canadian Psychiatric Research Foundation.
Dr. Alda has published over 160 original papers and book chapters, and serves on editorial boards of several journals (Bipolar Disorders, Open Neuroscience Journal, Open Psychiatry Journal, Pharmacopsychiatry, and Psychiatrie). He is a member of various scientific organizations, including the European College of Neuropsycho-pharmacology, American Society for Human Genetics, International Society for Psychiatric Genetics, Canadian College of Neuropsycho-pharmacology, and the International Group for the Study of Lithium Treated Patients (IGSLi) and the ConLiGen consortium.
Dr. Alda held the NCDEU Young Investigator Award from the US-based National Institute of Mental Health, the Intermediate Research Fellowship from the Ontario Mental Health Foundation, and twice the Independent Investigator Award from NARSAD. Prior to his return to Halifax, he was the Canada Research Chair Tier I at McGill University.
- Mood disorders: phenomenology, treatment, genetics, and neurobiology
- Psychiatric genetics, pharmacogenetics of psychotropic drugs
- Genetics of complex traits and their heterogeneity
Michael Bauer, M.D., Ph.D
Professor Michael Bauer, MD, PhD, is Director and Executive Chair at the Department of Psychiatry and Psychotherapy at the Medical Faculty of the Technische Universität Dresden, and physician-in-chief of the psychiatric hospital and outpatient clinics at the University Hospital Carl Gustav Carus in Dresden, Germany.
Dr. Bauer received his MD from the Freie Universität Berlin, Germany, and his PhD from the Institute of Molecular Biology and Biochemistry also at Freie Universität Berlin. From 1990-1996 he completed a residency in psychiatry and neurology at Benjamin Franklin University Medical Center in Berlin, Germany. From 1998 to 2002 he was a Visiting Professor of Psychiatry at the Neuropsychiatric Institute of the University of California at Los Angeles (UCLA). From 2002-2006 he was Deputy Head in the Department of Psychiatry and Psychotherapy at Charite-University of Medicine Berlin, in Berlin, Germany, and also Director of the Mood Disorders Research and Clinical Program at the Charité.
Dr. Bauer’s research interests include the neurobiology and treatment of mood disorders with an emphasis on bipolar disorder, and refractory depression and investigation of the thyroid system in mood disorders using neuroendocrine and functional brain imaging techniques.
He currently is the President of the International Group for the Study of Lithium-treated Patients, Chair of the German Society of Bipolar Disorder, Chair of the World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders, and editor of the journals “Pharmacopsychiatry” and “Der Nervenarzt”.
He has published more than 160 articles in peer-reviewed journals, 10 edited books and 54 book chapters and has been the recipient of several honors and awards, including the National Alliance for Research on Schizophrenia and Depression Young Investigator Award, the National Alliance for Research on Schizophrenia and Depression Independent Investigator Award 2005, the Judson Braun Research Scholarship at the University of California, Los Angeles, and the Deutsche Forschungsgemeinschaft Research Scholarship.
RH Belmaker, M.D.
Dr. Belmaker received his BA from Harvard College in 1967 and his MD from Duke Medical School in 1971. From 1972-74 he was a Clinical Associate at the National Institute of Mental Health in Bethesda, MD. Since 1974 he has held positions in academic psychiatry in Israel, first at the Jerusalem Mental Health Center 1974-1984 and then at Ben Gurion University of the Negev 1985 to the present.
Dr. Belmaker was a pioneer in biological psychiatry in Israel, and chaired the International College of Neuropsychopharmacology (CINP) meeting in Jerusalem in 1982. His research interests include affective disorders, especially mania, ECT, and second messenger mechanisms. In 1993 he submitted a grant request to National Alliance for Research on Schizophrenia and Depression proposing that TMS could be therapeutically useful in psychiatry, and was awarded the prestigious Distinguished Investigator Award to pursue this hypothesis. He has received the Anna Monika Prize for Research in Depression (1983), the Ziskind-Somerfeld Prize for Senior Research in Psychiatry (1993) and the European College of Neuropsychopharmacology Lilly Research Award (1996), and the National Alliance for Research on Schizophrenia and Depression Lifetime Achievement Falcone Award for research in affective disorder (2000) and the Research Prize of the World Federation of Societies of Biological Psychiatry (2004).
He is President of the CINP (International College of Neuropsychopharmacology). Husband of over 40 years, father of six children and grandfather of four and counting, Dr. Belmaker is an avid amateur archaeologist in Israel and scuba diver.
Professor Michael Berk is currently appointed as Chair of Psychiatry in the School of Medicine, Deakin University. He also is a Professorial Fellow at the University of Melbourne and the Mental Health Research Institute, and leads the first episode bipolar program at Orygen Youth Health Research Centre. He is immediate past President of the International Society of Bipolar Disorders, and Chairman of the Australasian Society of Bipolar Disorders. He has published over 350 papers on a range of topics with his research interests focusing on mood and psychotic disorders, particularly bipolar disorder and depression. His greatest contribution to the field is in the discovery and implementation of novel therapies. He has published over 20 self-initiated, non-industry randomised controlled trials, predominantly in bipolar disorder. He is a past committee member of both the Collegium Internationale Psychopharmacologicum and World Federation of Societies of Biological Psychiatry and is a member of a number of international advisory boards. He was the founding editor of The Journal of Depression and Anxiety, is associate editor of both the Australian and New Zealand Journal of Psychiatry and Early Intervention in Psychiatry, has served as guest editor or is on the editorial board of 12 other journals as well as being a reviewer of 30 journals.
Prof Berk is the recipient of a number of grants, including a NHMRC CCRE and 3 NHMRC project grants, two beyondblue grants and two Stanley Medical Research Institute awards and is a lead investigator on the CRE for Mental Health. He is regularly invited as a speaker at international meetings. In 2008, he was awarded the Australasian Society of Psychiatric Research Eli Lilly Oration, the Pathcare Smart Geelong Research and Learning Expo Health and Lifestyle award and the G Force Recruitment Researcher of the Year award for his work, and in 2009 received a commendation in the Ministers Award for Mental Health. Since relocating to Australia in 2001, he has established a new research unit at Barwon Health, which now has 15 researchers and 6 students engaged in 33 projects, multiple local, national and international collaborations, as well as heading a clinical Professorial Unit at the Geelong Clinic.
Hilary P. Blumberg, M.D.
The focus of Dr. Blumberg’s research is the utilization of brain scanning techniques to understand the neural systems that underlie emotional processing, and to investigate abnormalities in these neural systems in mood disorders. I have a particular interest in the cortico-limbic structures that include the amygdala, hippocampus and orbitofrontal cortex. I am especially interested in how genetic, developmental and environmental factors interact to influence the expression of abnormalities in these structures over the lifespan. I use a variety of magnetic resonance imaging (MRI) methods to study the brain including structural MRI to look at regional brain volumes, functional MRI to look at regional brain activity, and diffusion tensor MRI to look at the integrity of connections between structures.
Joe Calabrese, M.D.
Joseph Calabrese holds the Bipolar Disorders Research Chair and is Professor of Psychiatry at Case Western Reserve University. He is the Director of the Mood Disorders Program at the University Hospitals Case Medical Center in Cleveland, Ohio.
Dr. Calabrese also co-directs an NIMH-funded ‘Bipolar Disorders Research Centre, whose projects include research conducted by Bob Findling (Director of Child and Adolescent Psychiatry) on the phenomenology and treatment of juvenile bipolar, and research conducted by Martha Sajatovic (Director of Geriatric Psychiatry), whose projects include late life bipolar disorder, health services research, and qualitative methodology.The research center is dedicated to the improvement of clinical outcomes in under-served populations of bipolar disorder, including those with bipolar depression, rapid cycling, children and adolescents, adults currently abusing alcohol and/or drugs, forensic complications of bipolar disorder, those receiving care within community mental health centres, older adults, and members of the Ohio National Guard.
Dr Calabrese has received numerous research grants from the NIMH and Federal agencies and published over 300 peer-reviewed papers. His primary scientific focus is the short- and long-term treatment of bipolar disorder, with special emphasis on bipolar depression and the rapid cycling pattern of presentation. Dr. Calabrese was chosen by psychiatry residents to receive the ‘Best Teacher of the Year Award’ in three different years, received the NARSAD Lifetime Achievement Award for his research in bipolar disorder in 2005, Ellis Island Medal of Honor in 2006, and the Gerald L. Klerman Lifetime Achievement Award in 2008.
Kiki Chang, MD
Kiki Chang, MD, is Professor of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine, Division of Child Psychiatry. He is Director of the Pediatric Bipolar Disorders Clinic and Research Program, where he specializes in pediatric psychopharmacology and treatment of depression and bipolar disorder in children and adolescents. His research includes brain imaging, genetics, psychotherapy, and medication trials.
Dr. Chang graduated cum laude from Princeton University in 1988 and received his M.D. from the Tufts University School of Medicine in 1993. He completed his general psychiatry residency at the University of Cincinnati and his child psychiatry fellowship at Stanford University. After a postdoctoral research fellowship, Dr. Chang joined the Stanford faculty in 1999.
Dr. Chang is the recipient of the 2003 American Psychiatric Association/ AstraZeneca Young Minds in Psychiatry Award. He has been the recipient of two NARSAD Young Investigator Awards and has received a 5-year Career Development Award from the National Institutes of Health as well as an 5-year RO1 grant from the NIMH.
Dr. Chang is the author of numerous papers and book chapters regarding bipolar disorder and has presented widely at national and international scientific conferences and meetings.
Karl Deisseroth, M.D., Ph.D.
Dr. Deisseroth focuses on developing molecular and cellular tools to observe, perturb, and re-engineer brain circuits. His laboratory is based in the James H. Clark Center at Stanford and employs a range of techniques including neural stem cell and tissue engineering methods, electrophysiology, molecular biology, neural activity imaging, animal behavior, and computational neural network modeling. Also a clinician in the psychiatry department, Professor Deisseroth employs novel electromagnetic brain stimulation techniques in human patients for therapeutic purposes.